18 results about "False-positive result" patented technology

The invention relates to application of a Fe < 3 + >-ATP-CK cascade regulation type carbon dot fluorescent probe in dynamic monitoring of creatine kinase content, and relates to the field of new application of carbon dots. Fluorescence of B, N-CDs is quenched by Fe < 3 + >, and then fluorescence is recovered after ATP is added through specific binding of Fe < 3 + > and ATP. When CK catalyzes ATP to react with Cr, fluorescence is quenched again due to reduction of the ATP content. On the basis of high-selectivity competitive combination of Fe < 3 + > and ATP, interference of ADP, AMP and other analogues can be eliminated. The multiple verification mechanisms of Fe < 3 + > quenching, ATP recovery and CK re-quenching significantly reduce the false positive result, and enhance the detection reliability. A portable sensing platform constructed based on a smart phone establishes a new method for bedside detection of CK, establishes a brand new strategy for CK detection, and shows a wide prospect in rapid screening application of clinical diagnosis of myocardial infarction and the like.

The invention discloses a preparation method of a monoclonal antibody for detecting trichophyton rubrum and application of the monoclonal antibody in fungal skin disease detection, and belongs to the field of biological medicine. The monoclonal antibody provided by the invention only has specific reaction with trichophyton rubrum, and has no cross reaction with common fungi such as trichophyton mentagrophytes, epidermophyton flocculent, candida albicans, malassezia and the like and normal flora of a human body, so that a false positive result is effectively avoided. Based on the double-antibody sandwich principle, the detection sensitivity can reach 200 pg / mL level, trace trichophyton rubrum in a clinical sample can be detected, and the positive rate is obviously higher than that of direct microscopic examination. The whole detection process can be completed within 15-20 min and is far faster than fungus culture for several weeks, a rapid diagnosis basis can be provided for doctors, and early treatment is facilitated. The kit provided by the invention has standardized operation steps, does not need complex instruments and special training, and is suitable for popularization and use in clinical laboratories of hospitals at all levels, outpatient clinics of dermatology and even basic medical institutions.

The application discloses a biomarker for prognosis evaluation of extrahepatic cholangiocarcinoma, a prognosis risk evaluation system and application, and belongs to the technical field of bioinformatics. The application adopts the combination of miR-34c-5p, miR-100-5p, miR-193b-5p, miR-122-5p, miR-5588-5p and miR-122-3p as a biomarker, can effectively improve the accuracy of differential diagnosis of extrahepatic cholangiocarcinoma, can distinguish extrahepatic cholangiocarcinoma patients from healthy people and benign biliary disease patients with high precision, and overcomes the limitation that traditional tumor markers such as CA19-9 are prone to false positive results in benign biliary diseases. Meanwhile, the expression level change of the biomarker combination can dynamically reflect the postoperative tumor load change, and is helpful for accurately evaluating the surgical effect.

The invention discloses a reusable dual-mode aptamer biosensor for detecting clostridium perfringens, which is characterized by comprising a competitive chain CP-C, a CeO2 (at) PANI nano composite material, a closed bipolar electrode system and an aptamer functionalized magnetic bead probe. According to the invention, the high-affinity nucleic acid aptamer is combined with the specific extracellular electron transfer mechanism of the clostridium perfringens viable bacteria for the first time, a new viable bacteria detection sensing strategy free of nucleic acid extraction and target gene amplification is constructed, and the biosensor can specifically recognize the viable clostridium perfringens, and can be used for detecting the viable bacteria of the clostridium perfringens. According to the present invention, with the detection method, the false positive result caused by the existence of dead bacteria is avoided, the detection can be rapidly completed within 3 min, the voltage signal and the G value signal are mutually proved, the false positive or false negative of the single signal detection is effectively avoided, the detection limit is as low as 2.50 CFU / mL, and the excellent anti-interference ability in the complex food matrix such as chicken and milk is provided; the core element ITO glass electrode can be continuously and repeatedly used for 12 times, and the performance is not obviously attenuated.

This application belongs to the field of immunoassay technology, specifically relating to specific binding proteins of hepatitis B viruses (MHBs), nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides a specific binding protein of MHBs with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with large and small proteins, thus improving detection specificity and avoiding false positive results. The specific binding protein of MHBs in this application can bind to a chemiluminescent detection system, thereby achieving highly sensitive detection of MHB antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

This application belongs to the field of immunoassay technology, specifically relating to LHBs-specific binding proteins, nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides an LHBs-specific binding protein with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with medium and small proteins, thus improving detection specificity and avoiding false positive results. The LHBs-specific binding protein of this application can bind to chemiluminescent detection systems, thereby achieving highly sensitive detection of LHBs antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

The invention relates to a method and a product for preventing false positive results in real-time fluorescent quantitative PCR detection of pathogens. The positive reference template provided by the invention is used for replacing a positive control template, so that a false positive result caused by the fact that a test sample is polluted by the positive control template in real-time fluorescent quantitative PCR detection of pathogens is prevented.

The application discloses a primer probe combination, a kit and application for detecting Nocardia, a mycobacterium tuberculosis complex and mycobacterium, and belongs to the technical field of genetic engineering. The technical problem to be solved is that there is a lack of a nucleic acid detection tool for Nocardia, the mycobacterium tuberculosis complex and mycobacterium in the prior art, which is high in sensitivity, high in specificity and simple in operation. The technical solution is characterized in that the primer probe combination comprises a primer probe for detecting Nocardia, a primer probe for detecting the mycobacterium tuberculosis complex, a primer probe for detecting mycobacterium and a primer probe for detecting an internal standard control. The primer probe combination can simultaneously screen Nocardia, the mycobacterium tuberculosis complex and mycobacterium, quickly and simply confirms pathogenic species, saves time, manpower and reagent cost, and has the advantages of high specificity, a low minimum detection limit and prevention of false negative or false positive results.

A tumor stroma imaging agent with a chemical structural formula (I):is provided, where R is hydrogen or fluorine. Compared with the prior art, the tumor stroma imaging agent exhibits significant affinity for fibroblast activation protein (FAP), high uptake for a malignant tumor with high FAP expression in a tumor stroma, and high sensitivity and specificity for the diagnosis of a malignant tumor, and is not prone to false positives. Therefore, the tumor stroma imaging agent can be effectively and safely used for the diagnosis and treatment of various malignant tumors with a prolonged half-life and an extended window period, which is conducive to clinical application.

The invention provides a near-infrared AIE fluorescent probe as well as a preparation method and application thereof. The fluorescent probe has obvious AIE property, aggregation-induced emission (AIE) effect and good light stability, can realize seven-day imaging of CAR-T cells, can target CAR-T cell mitochondria, cannot leak to other cells, and avoids false positive results. Meanwhile, the probe has good biocompatibility, does not influence CAR-T cells to secrete key cell factors IFN-gamma, and does not damage the killing function of the CAR-T cells on tumor cells. In a small animal living body level, the probe N-6 is used for tracing CD19 CAR-T cells in a Raji subcutaneous tumor model mouse, a result shows that a fluorescence signal can be continuously observed for 7 days, and the CAR-T cells are continuously enriched in tumor tissues and liver tissues, which indicates that the probe N-6 can monitor the dynamic distribution process of the CAR-T cells in vivo in real time.

To eliminate and improve the risk of false positive results in sandwich ELISA.SOLUTION: A method for determining an analyte suspected of being present in a sample, the method comprising: (i) an anchor layer present on a solid support; (ii) a first binding agent capable of specifically binding to the analyte, wherein the first binding agent is anchored to the anchor layer and comprises at least one detectable label; (iii) a second binding agent capable of specifically binding to the analyte when bound to the first binding agent, wherein the second binding agent is immobilized on a solid support; and contacting under conditions and for a time allowing specific binding of the analyte suspected of being present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent, and detecting formation of a complex of the first binding agent, the analyte and the second binding agent, whereby the analyte is determined.SELECTED DRAWING: Figure 1

The application discloses a 21-hydroxylase deficiency screening kit and application thereof, relates to the blood analysis technical field, and a steroid hormone marker composition of 21-hydroxylase deficiency, wherein the nine markers comprise 17alpha-hydroxyprogesterone, androstenedione, 11-deoxycortisol, 21-deoxycortisol, cortisol, corticosterone, progesterone, dihydrotestosterone and 11-deoxycorticosterone; the kit can be used for screening 21-hydroxylase deficiency, 11beta-hydroxylase deficiency, 17alpha-hydroxylase deficiency and other types of diseases; the kit comprises detection components for detecting the hormones; compared with a traditional time-resolved fluorescence immunoassay method, the LC-MS / MS multi-index combined detection scheme adopted in the application can significantly reduce false positive results; and invalid recall, unnecessary family anxiety and medical burden caused by false positive results are greatly reduced.

Disclosed herein are methods for detecting a false positive initial sample result in a subject initially identified as having, or at risk for, cancer. Such methods can be performed on a sample obtained from the subject while undergoing a colonoscopy. Thus, methods can be useful for confirming or contradicting the initial identification that the high risk subject is at risk for cancer. Altogether, such methods are valuable for improving precision of a cancer test.

Provided are compositions and methods useful to the determination of whether a microbial contaminant is present in a biological therapeutic production process. Specifically, an artificial positive amplification control plasmid and unique quantitative PCR detection probe are provided, which enables the rapid and real-time detection of a false positive result.

Blood sample optimization systems and methods are described that reduce or eliminate contaminates in collected blood samples, which in turn reduces or eliminates false positive readings in blood cultures or other testing of collected blood samples. A blood sample optimization system can include a blood sequestration device located between a patient needle and a sample needle. The blood sequestration device can include a sequestration chamber for sequestering an initial, potentially contaminated aliquot of blood, and may further include a sampling channel that bypasses the sequestration chamber to convey likely uncontaminated blood between the patient needle and the sample needle after the initial aliquot of blood is sequestered in the sequestration chamber.

The invention discloses a combined marker for colorectal cancer detection and application of the combined marker. The combined marker is composed of an ALX4 gene, an SFRP2 gene, an SEPTIN9 gene, an SDC2 gene and a TFPI2 gene. Experiments prove that the ALX4 gene, the SFRP2 gene, the SEPTIN9 gene, the SDC2 gene and the TFPI2 gene are combined to diagnose the early colorectal cancer, the operation is simple, the consumed time is short, the sensitivity and the specificity are relatively high, the detection rate can be effectively improved, and false positive results are reduced. The method has an important application value.

The utility model belongs to the field of immune chromatography technology, disclose a kind of double control flow high sensitivity immune chromatography device, including bottom plate, sample pad, binding pad, dissolved breakaway isolation pad, chromatography pad and bibulous pad are sequentially arranged in sample flow direction on bottom plate, chromatography pad is sequentially provided with IgG detection line, IgM detection line and quality control line in sample flow direction, two hydrophobic isolation zones are provided on chromatography pad, one of which is located between IgG detection line and IgM detection line, another hydrophobic isolation zone is arranged between IgM detection line and quality control line, the utility model is provided with two hydrophobic isolation zones on chromatography pad, respectively between IgG detection line and IgM detection line, between IgM detection line and quality control line, using the strong hydrophobicity of polytetrafluoroethylene and the design of full coverage along the width direction, form physical barrier to block transverse flow, significantly reduce the generation of false negative, false positive result from the root, significantly improve the reliability of multiple detection.